Evidence map›Paper›PMID 32142223›Full record

ArticleCancer medicine2020

Reliable blood cancer cells' telomere length evaluation by qPCR.

Joana Ropio, Alain Chebly, Jacky Ferrer, Martina Prochazkova-Carlotti, Yamina Idrissi, Lamia Azzi-Martin, David Cappellen, Anne Pham-Ledard, Paula Soares, Jean-Philippe Merlio and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Patchouli Ethanol ExtractAging medicine (Milton (N.S.W)) · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Spotlight onGenes · 2023
    Article
  9. Article
  10. Review
  11. Cross-species Association Between Telomere Length and Glucocorticoid Exposure.The Journal of clinical endocrinology and metabolism · 2021
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Joana RopioBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Alain CheblyBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.ORCID 0000-0001-5582-2923
Jacky FerrerBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Martina Prochazkova-CarlottiBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Yamina IdrissiBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Lamia Azzi-MartinBordeaux University, UFR des Sciences Médicales, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Bordeaux, France.
David CappellenBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Anne Pham-LedardBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Paula SoaresInstituto de Investigação e Inovação em Saúde, Porto, Portugal.ORCID 0000-0001-9607-6998
Jean-Philippe MerlioBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.
Edith ChevretBordeaux University, INSERM U1053 Bordeaux Research in Translational Oncology (BaRITOn), Cutaneous Lymphoma Oncogenesis Team, Bordeaux, France.ORCID 0000-0002-9724-8437
Inserm · FRUniversidade do Porto · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTelomere shortening is linked to a range of different human diseases, hence reliable measurement methods are needed to uncover such associations. Among the plethora of telomere length measurement methods, qPCR is reported as easy to conduct and a cost-effective approach to study samples with low DNA amounts.

methodsCancer cells' telomere length was evaluated by relative and absolute qPCR methods.

resultsRobust and reproducible telomere length measurements were optimized taking into account a careful reference gene selection and by knowing the cancer cells ploidy. qPCR data were compared to "gold standard" measurement from terminal restriction fragment (TRF).

conclusionsOur study provides guidance and recommendations for accurate telomere length measurement by qPCR in cancer cells, taking advantage of our expertise in telomere homeostasis investigation in primary cutaneous T-cell lymphomas. Furthermore, our data emphasize the requirement of samples with both, high DNA quality and high tumor cells representation.

Indexed as

AgedAged, 80 and overApoptosisCase-Control StudiesCell ProliferationHumansLeukocytes, MononuclearLymphoma, Large-Cell, AnaplasticMiddle AgedReal-Time Polymerase Chain ReactionSchizophreniaSkin NeoplasmsTelomere HomeostasisTumor Cells, CulturedcancerqPCRsouthern blottelomere lengthtumor

Identifiers

PMID32142223
PMCPMC7196062
OpenAlexW3009474127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.